- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07613710
A Trial to Test the Safety and Tolerability of Lu AH69593 in Adults That Are Healthy or Have Narcolepsy
Interventional, Randomized, Double-blind, Sequential-group, Placebo-controlled, Single- and Multiple-ascending-dose Trial Investigating Safety, Tolerability, and Pharmacokinetics of Lu AH69593 in Healthy Participants, Including Open-label Cohorts to Explore Pharmacodynamic Properties in Participants With Narcolepsy, and Food Effect in Healthy Participants
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 1
Kontakter och platser
Studiekontakt
- Namn: Email contact via H. Lundbeck A/S
- Telefonnummer: +45 36301311
- E-post: HQ_Medinfo@Lundbeck.com
Studieorter
-
-
-
Helsinki, Finland, 00380
- Rekrytering
- Terveystalo Helsinki, Sleep Clinic
-
Turku, Finland, 20520
- Avslutad
- CRST, Clinical Research Services Turku
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
- Vuxen
Tar emot friska volontärer
Beskrivning
Key Inclusion Criteria:
For all participants in any trial Part (A, B, C and D):
- The participant has a resting supine pulse ≥45 and ≤100 beats per minute (bpm) at the Screening Visit and at the Baseline Visit.
Specifically for participants in trial Part A, B, and D:
- The participant has a body mass index (BMI) ≥18.5 and ≤30 kilograms (kg)/square meter (m^2) at the Screening Visit.
- The participant has a normal circadian rhythm, defined as a person who usually wakes up between 6:00 and 9:00 a.m. and goes to sleep between 9:00 p.m. and midnight.
- The participant is ≥18 and ≤55 years of age at the Screening Visit.
Specifically for participants in trial Part C:
- The participant has a BMI ≥18.5 and ≤35 kg/m^2 at the Screening Visit.
- The participant has NT1, diagnosed according to International Classification of Sleep Disorders, 3rd edition criteria, with a history of disease diagnosis >3 months prior to the Screening Visit.
- The participant is ≥18 and ≤64 years of age at the Screening Visit.
Key Exclusion Criteria:
For all participants in any trial Part (A, B, C and D):
- The participant has previously been enrolled in this trial.
- The participant has previously been dosed with Lu AH69593.
- The participant has participated in a clinical trial <30 days prior to the Screening Visit.
- The participant is pregnant, breastfeeding, intends to become pregnant, or is of childbearing potential and not willing to use adequate contraceptive methods.
- The participant has a history of cancer, other than basal cell or Stage 1 squamous cell carcinoma of the skin or adequately treated cervical intraepithelial neoplasia, that has not been in remission for >5 years prior to the first dose of investigational medicinal product (IMP).
- The participant has worked shifts, including night duty, or has travelled across >3 time zones <2 weeks prior to the first dose of IMP.
- The participant trains/exercises intensively, for example, for a marathon or triathlon, or at a competitive level.
Specifically for participants in trial Part A, B and D:
- The participant has had a clinically significant illness from which he/she recovered <4 weeks prior to the first dose of IMP.
Specifically for Participants in trial Part B and C:
- The participant is at significant risk of suicide based on medical history, mental status, investigator judgement, or the C-SSRS answer of 'yes' to suicidal ideation question 4 or 5 or 'yes' to suicidal behaviour, within the last 6 months on the C-SSRS at the Screening Visit or 'Since last visit' at the Baseline Visit Day -1.
Specifically for participants in trial Part C:
- The participant has any other disorder for which the treatment takes priority over treatment of narcolepsy or is likely to interfere with trial treatment or impair treatment compliance.
- The participant has a current medical disorder, other than NT1, associated with excessive daytime sleepiness (EDS).
Note: Other protocol-defined inclusion and exclusion criteria may apply.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Sekventiell tilldelning
- Maskning: Fyrdubbla
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Part A (Single Ascending Dose [SAD] in Healthy Participants): Lu AH69593 or Placebo
Participants will receive single oral dose of Lu AH69593 or placebo.
|
Placebo kommer att administreras enligt det schema som anges i armbeskrivningen.
Lu AH69593 will be administered per schedule specified in the arm description.
|
|
Experimentell: Part B (Multiple Ascending Dose [MAD] in Healthy Participants): Lu AH69593 or Placebo
Participants will receive Lu AH69593 or placebo orally for 10 days.
|
Placebo kommer att administreras enligt det schema som anges i armbeskrivningen.
Lu AH69593 will be administered per schedule specified in the arm description.
|
|
Experimentell: Part C (MAD in Participants With Narcolepsy Type 1 [NT1]): Lu AH69593
Participants will receive Lu AH69593 orally for 84 days.
|
Lu AH69593 will be administered per schedule specified in the arm description.
|
|
Experimentell: Part D (Food Effect in Healthy Participants): Lu AH69593
Participants with receive two single oral doses of Lu AH69593 in fasting or fed condition.
|
Lu AH69593 will be administered per schedule specified in the arm description.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Tidsram: Baseline up to Day 90
|
Baseline up to Day 90
|
|
Bond Lader Visual Analogue Scale (VAS) dimension scores (Alertness, Contentedness, and Calmness)
Tidsram: Baseline up to Day 84
|
Baseline up to Day 84
|
|
Psychomotor Vigilance Task (PVT) Parameter - Change From Baseline in Reaction Time to Stimuli
Tidsram: Baseline, up to Day 11
|
Baseline, up to Day 11
|
|
PVT Parameter - Change From Baseline in Number of Errors of Omission
Tidsram: Baseline, up to Day 11
|
Baseline, up to Day 11
|
|
PVT Parameter - Change From Baseline in Number of Errors of Commission (Response Without Stimulus)
Tidsram: Baseline, up to Day 11
|
Baseline, up to Day 11
|
|
Number of Participants With Suicidal Ideation and Behaviour Based on the Columbia-Suicide Severity Rating Scale (C-SSRS)
Tidsram: Baseline up to Day 90
|
Baseline up to Day 90
|
|
Area Under the Curve (AUC) From Zero to Time of Last Quantifiable Concentration (AUC0-t) of Lu AH69593
Tidsram: Up to 84 days
|
Up to 84 days
|
|
Maximum Observed Plasma Concentration (Cmax) of Lu AH69593
Tidsram: Up to 84 days
|
Up to 84 days
|
|
Time to Reach Cmax (Tmax) of Lu AH69593
Tidsram: Up to 84 days
|
Up to 84 days
|
|
AUC From Time Zero to Infinity (AUC0-inf)
Tidsram: Up to 6 days
|
Up to 6 days
|
Samarbetspartners och utredare
Sponsor
Utredare
- Studierektor: Email contact via H. Lundbeck A/S, H. Lundbeck A/S
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 20653A
- 2024-511073-29-00 (Ctis)
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .